Nepafenac 0.3% Oph Susp

DRUG3 trials

Sponsors

University Hospital of Patras, Actavis Inc., Nemocnice Kolín

Conditions

CataractCataract SurgeryMacular OedemaNSAID (Non-Steroidal Anti-Inflammatory Drug)Pain

Phase 3

Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

CompletedNCT03499873

Actavis Inc.Cataract

Start: 2018-03-28End: 2018-12-18Updated: 2021-02-16

Unknown Phase

Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections

CompletedNCT03406689

University Hospital of PatrasPain

Start: 2017-09-01End: 2018-03-28Updated: 2018-04-04

Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery

RecruitingNCT07178639

Nemocnice KolínCataract Surgery, Macular Oedema, NSAID (Non-Steroidal Anti-Inflammatory Drug)

Start: 2025-08-01End: 2026-02-28Target: 150Updated: 2025-09-17